CTLA4 and Hodgkins lymphoma: While earlier studies have shown that PD-L1 and CTLA-4 blockade have therapeutic benefit in some cancers including melanoma and Hodgkins diseases, other cancers such as CRC except for a small subset of tumors are non-responsive (78).